Literature DB >> 25558841

Bladder cancer in 2014: From the genomic frontier to immunotherapeutics.

Andrew T Lenis1, Karim Chamie1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25558841     DOI： 10.1038/nrurol.2014.369

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  The costs of non-muscle invasive bladder cancer.

Authors:  Andrew C James; John L Gore
Journal:  Urol Clin North Am       Date:  2013-02-13       Impact factor: 2.241

Review 2.  Prognostic and predictive markers for the new immunotherapies.

Authors:  Kathleen M Mahoney; Michael B Atkins
Journal:  Oncology (Williston Park)       Date:  2014-11       Impact factor: 2.990

3.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Authors:  Thomas Powles; Joseph Paul Eder; Gregg D Fine; Fadi S Braiteh; Yohann Loriot; Cristina Cruz; Joaquim Bellmunt; Howard A Burris; Daniel P Petrylak; Siew-leng Teng; Xiaodong Shen; Zachary Boyd; Priti S Hegde; Daniel S Chen; Nicholas J Vogelzang
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Authors:  Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

5.  Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis.

Authors:  John L Gore; Julie Lai; Claude M Setodji; Mark S Litwin; Christopher S Saigal
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

6.  Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Authors:  Nikhil Wagle; Brian C Grabiner; Eliezer M Van Allen; Eran Hodis; Susanna Jacobus; Jeffrey G Supko; Michelle Stewart; Toni K Choueiri; Leena Gandhi; James M Cleary; Aymen A Elfiky; Mary Ellen Taplin; Edward C Stack; Sabina Signoretti; Massimo Loda; Geoffrey I Shapiro; David M Sabatini; Eric S Lander; Stacey B Gabriel; Philip W Kantoff; Levi A Garraway; Jonathan E Rosenberg
Journal:  Cancer Discov       Date:  2014-03-13       Impact factor: 39.397

7.  Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.

Authors:  Eduardo Solsona; Rosario Madero; Venancio Chantada; Jesus M Fernandez; Juan A Zabala; José A Portillo; Jose M Alonso; Ander Astobieta; Miguel Unda; Luis Martinez-Piñeiro; Mariano Rabadan; Antonio Ojea; Jesus Rodriguez-Molina; Pastora Beardo; Pedro Muntañola; Matias Gomez; Manuel Montesinos; Jose A Martinez Piñeiro
Journal:  Eur Urol       Date:  2014-10-06       Impact factor: 20.096

8.  PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

Authors:  Brant A Inman; Thomas J Sebo; Xavier Frigola; Haidong Dong; Eric J Bergstralh; Igor Frank; Yves Fradet; Louis Lacombe; Eugene D Kwon
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

9.  Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link.

Authors:  Karim Chamie; Eric Ballon-Landa; Jeffrey C Bassett; Timothy J Daskivich; Meryl Leventhal; Dennis Deapen; Mark S Litwin
Journal:  Cancer       Date:  2014-10-22       Impact factor: 6.921

10.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962
  10 in total
  3 in total

Review 1.  Immune checkpoint blockade therapy for bladder cancer treatment.

Authors:  Jayoung Kim
Journal:  Investig Clin Urol       Date:  2016-05-26

Review 2.  Unmasking molecular profiles of bladder cancer.

Authors:  Xuan-Mei Piao; Young Joon Byun; Wun-Jae Kim; Jayoung Kim
Journal:  Investig Clin Urol       Date:  2018-02-01

3.  Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.

Authors:  Wen Cheng; Dian Fu; Feng Xu; Zhengyu Zhang
Journal:  Oncogenesis       Date:  2018-01-23       Impact factor: 7.485
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.